Adherent cell assays have lagged behind in automation, slowing drug discovery. Semarion’s SemaCyte® microcarrier platform streamlines these workflows by making adherent cells assay-ready, improving ...

The primary causes of disability and mortality in the US are chronic diseases such as cancer, neurodegenerative disorders, cardiovascular disease, obesity, arthritis, and diabetes. The increase in ...

In the complex process of producing a gene therapy, bioprocessors depend on assays to monitor the attributes of the product at various stages. Scientists at Thermo Fisher Scientific focus on ...

In the ever-evolving landscape of biomedical research, the need for reliable, consistent, and ready-to-use cell models has never been more critical. ATCC, a leading provider of biological materials, ...

Role of Minimally Invasive Techniques in the Management of Early-Stage Carcinoma of the Uterine Cervix What level of sensitivity is required is still unclear. Recently, Parsons et al 37 showed that ...

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

Persistent outcome disparities, particularly worse prognoses for Black women with breast cancer, persist even within the same genomic risk categories. Effective management requires integrating genomic ...

This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms ...